ABSTRACT: Although crystal polymorphism of carbamazepine (CBZ), an anticonvulsant used to treat epilepsy, has been known for decades, the phenomenon has only recently been noted for its keto-derivative oxcarbazepine (OCB). Here it is demonstrated that OCB possesses at least three anhydrous polymorphs. Although all forms are morphologically similar, making differentiation between crystal modifications by optical microscopy difficult, powder X-ray diffraction, Raman spectroscopy, and thermomicroscopy show distinctive differences. These techniques provide an efficient method of distinguishing between the three polymorphs. The crystal structure of form II of OCB is reported for the first time and the structure of form I has been redetermined at low temperature. Remarkably, both the molecular conformation and crystal packing of form II are in excellent agreement with the blind prediction made in 2007. ß
INTRODUCTION
Polymorphism occurs when a molecule is able to form multiple crystal structures where the packing and/or molecular conformation differs between structures. 1 Although this is far from a universal occurrence in organic compounds, 2 crystal polymorphism has considerable technical importance in industry, especially among pharmaceuticals, where the presence of different structures can affect dissolution rate, solubility, and bioavailability, among other physical characteristics. 1 Despite being highly investigated, the phenomenon of polymorphism continues to present new challenges. In molecular solids, hydrogen bonding and molecular flexibility are thought to be factors contributing to increased propensity towards polymorphism, 3 yet predicting the presence of polymorphic behavior, much less the structure of the polymorphs, remains an outstanding challenge. The conditions under which a crystal is grown clearly affect the crystal structure in polymorphic systems. Recently, insoluble polymers have been utilized to selectively control the crystallization of one polymorph over another. 4 The use of these polymeric heteronuclei has become an efficient and effective tool for screening for polymorphic behavior and the discovery of new polymorphs 4, 5 offering the potential to shed light on this fundamental issue in solid-state chemistry. Here we disclose our success in applying polymer-induced heteronucleation to solid form discovery for oxcarbazepine.
Carbamazepine (CBZ) (Fig. 1) , an important anticonvulsant, exhibits four structurally characterized polymorphs, 6 whereas its dihydro derivative (10,11-dihydrocarbamazepine) is trimorphic. [7] [8] [9] Its keto-derivative, oxcarbazepine (OCB) (Fig. 1) , also used as an anticonvulsant, is believed to also be polymorphic and patent literature claims a total of five polymorphs and a solvate albeit with levels of characterization inadequate to prove that these are novel forms. 10, 11 The characterization of three anhydrous polymorphs is reported herein. The commercially available form I crystallizes in the monoclinic space group P2 1 /c, with cell constants of a ¼ 5.276(2) Å , b ¼ 9.307(4) Å , c ¼ 24.841(7) Å , and b ¼ 95.64(2) 8. 12 The possibility of other structures for OCB has been suggested by computational studies, 13 although these have yet to realize experimental verification. One form proposed by Cabeza et al. appears to have a similar powder X-ray diffraction pattern to that of a form suggested in the patent literature. 10, 11 The present study reveals two additional forms of OCB, including one that matches the prediction of Cabeza et al., making it, at least, a trimorphic system. This observation contributes to the mounting evidence that the basic backbone of carbamazepine and urea functionality constitute a polymorphophore. 14 The two newly discovered forms of OCB reported herein, form II and form III, along with form I have been characterized by Raman spectroscopy, differential scanning calorimetry (DSC), thermomicroscopy, and powder X-ray diffraction (PXRD). The structure of form I was redetermined at low temperature. The crystal structure of form II was solved and found to be in good agreement with that predicted by Cabeza et al. 13 
EXPERIMENTAL Materials
Commercial OCB was obtained from Orgamol (Evionnaz, Switzerland). Toluene (ACS grade) and methanol (ACS grade) were purchased from Fisher Scientific (Pittsburgh, PA). Ethylene/vinyl acetate copolymers and high-density polyethylene were purchased from Scientific Polymer Products, Inc. (Ontario, NY).
Preparation of OCB Polymorphs
Form I of OCB was obtained directly from the bottle and from the evaporation of a methanol solution. Various concentrations were used, with higher concentrations yielding larger, better quality crystals. Form II was produced by dissolving 25.0 mg of OCB in 20 mL of toluene and heating the solution to 1158C until homogeneous. The solution was then allowed to cool to room temperature or placed in an ice bath until crystals were formed. The small needles (in most cases more powder-like than individual crystals) were collected after about an hour. Seeding of supersaturated toluene solutions (2.5 mg/mL) of oxcarbazepine at room temperature with form II seeds consistently yielded bulk form II, whereas the cooling of the solution alone yielded either form I or form II. Form III was obtained through the evaporation of methanol solutions (5 mg/mL) in the presence of ethylene/vinyl acetate copolymers or high-density polyethylene at room temperature.
Powder X-Ray Diffraction PXRD patterns were obtained on a Bruker D8 Advance diffractometer operating at 40 kV and 40 mA with a copper source between 3 and 508 2u with a step size of 0.0208. The step time for forms I and II was 5 s and that for form III was 30 s. Samples were measured directly on a glass slide at room temperature.
Single Crystal X-Ray Diffraction
All measurements were made on a Rigaku R-AXIS SPIDER diffractometer with an image plate detector using graphite monochromated Cu-Ka radiation (1.5406 Å ). The data collection was made at 95 K with the sample mounted on a MiTeGen MicroMount TM . The structure was solved by direct methods. 15 All calculations were performed using the CrystalStructure crystallographic software package 16 except for refinement, which was performed using SHELXL-97. 
Raman Spectroscopy
Raman spectra were recorded on a Renishaw inVia Raman Microscope equipped with a 20Â objective and utilizing a 633 nm HeNe laser. The scan range was 3600-100 cm À1 using three scans of length 60 s per spectrum. A silicon standard was used to calibrate the instrument.
Infrared Spectroscopy
IR spectra were obtained with a Perkin-Elmer AutoIMAGE FTIR microscopy system in transmission mode using 100 scans per spectrum.
Thermomicroscopy
A Mettler Toledo FP82HT hot stage using an FP90 control processor was used for thermomicroscopy. The sample was observed under polarized light with a Leica DMLP microscope. Samples were heated from 30 to 2208C at a rate of 58C/min. Forms II and III were also heated until each fully transformed and then allowed to cool. The transformation product was then identified using Raman spectroscopy and/or PXRD.
Differential Scanning Calorimetry
DSC was performed on a TA Instruments DSC Q10. Samples were placed in aluminum hermetic pans and sealed using a TA Instruments crimper. The temperature range was 20-3008C with a heating rate of 108C/min. Figure 2 presents the powder patterns. 
RESULTS AND DISCUSSION

Raman Spectroscopy
Although the Raman spectra of forms I and II are very similar, they possess several regions where they can be differentiated. The characteristic areas where all three polymorphs are easily discriminated from one another are 100-200, 700-800, 1100-1300, 1500-1700, and 2900-3400 cm
À1
. . Here it can be observed that forms I and II have a similar hydrogen bonding motif within their crystal structure (see below), whereas form III is different as evidenced by the missing peak around 3340 cm À1 . Forms I and II also each have a peak around 3470 cm À1 that is shifted to 3340 cm À1 in the spectrum of form III. A complete list of peaks is shown in Table 2 and the spectra are presented in Figure 3 .
Infrared Spectroscopy
The IR spectra reveal the structural similarities and disparities between the polymorphs. From the spectra it can be concluded that the hydrogen bonding scheme exhibited by forms I and II are very similar. Form III has a different hydrogen bonding motif. In forms I and II the hydrogen bonding motif can be attributed to peaks at about 3471 and 3345 cm À1 , while in form III a significant shift and the addition of one peak is observed (3303, 3353, and 3435 cm À1 ). Other major differences occur in the carbonyl region that can be attributed to the hydrogen bonding present in the crystal structure. In this region the peak that is at 1734 cm À1 in form I and 1733 cm À1 in form II disappears entirely from the spectrum of form III. Another significant dissimilarity is between 900 and 1000 cm À1 . Form I has peaks at 923, 956, and 985 cm À1 , while form II has peaks at 922, 959, and 994 cm À1 and form III has peaks at 922, 949, 968, and 997 cm
À1
. The IR spectra are shown in Figure 4 and the peak data are tabulated in Table 3 .
Thermomicroscopy/DSC
The behavior of oxcarbazepine during heating was observed on a hot stage (58C/min) under crossed polarizers. No transitions were observed in form I before it melted. The DSC curve of form I showed an endotherm (melt/decomposition) with an onset of 222.68C at a rate of 108C with an enthalpy of 9.64 kcal/mol. Thermomicroscopy proved that for all polymorphs melting and decomposition occurred simultaneously and this contributes to the large melting range measured. During decomposition the melt turns from colorless to yellow. The decomposition of oxcarbazepine is dependent upon the crystal size, with smaller and more defective crystals decomposing before larger ones.
A transition between 118 and 1508C was observed during the heating of form II. The temperature of this transition is highly dependent on crystal size and quality, with smaller crystals having more defects observed to transform before larger more perfect crystals. The DSC thermogram for form II exhibited an endothermic transition centered at 127.68C followed immediately by a broad exothermic transition centered at 165.88C. The approximate enthalpy of the endotherm is 0.23 kcal/mol while that of the exotherm was 0.42 kcal/mol. The endotherm is somewhat less than the predicted energy difference of 0.61 kcal/mol separating calculated form I and the next most stable form of Cabeza et al. 13 The ensuing melt/decomposition has an onset of 218.28C with an enthalpy of 7.97 kcal/mol. In order to determine which modification form II transformed into during heating, a sample was heated to 1608C and held there for 5 min. The sample was allowed to cool to room temperature. Raman microscopy and PXRD was performed on the product, which proved to be form I.
Form III showed a small transition between 115 and 1258C. The melt occurs between 210 and 2168C. The thermogram of form III shows a large endothermic transition between 58 and 1508C with a melt/decomposition onset of 210.08C. The enthalpy of the transition is 6.23 kcal/mol. To determine which polymorph form III had transformed into, a sample was heated to 1508C and held there for 5 min. Upon cooling to room temperature, the sample was found to be form I by Raman microscopy. In all of the polymorphs the melt was concomitant with decomposition. The DSC thermograms are presented in Figure 5 . Single Crystal X-Ray Diffraction
The crystal structure of form I was re-determined at low temperature and that of form II was solved for the first time (Tab. 4, Figs. 6 and 7) . The molecular conformation in forms I and II are similar. In form I, the azepine ring is in a twistboat conformation. The angle between the planes defined by the benzene rings is 638. The carboxamide group is extended above the rest of the molecule and participates in hydrogen bonding directed by the carbonyl of the carboxamide group on one molecule binding with the hydrogen of the NH 2 of next molecule creating infinite chains along the b-axis. The length of the hydrogen bond ðO Á Á Á NÞ is 2.77 Å . This differs dramatically from the anti-hydrogen bonded dimers observed in the four polymorphs of carbamazepine. 6 The second hydrogen in the carboxamide functionality participates in N À H Á Á Á p bonding with the benzene ring nearest to it. In addition to hydrogen bonding, C À H Á Á Á O interactions are present between the carbonyl of the azepine ring and a hydrogen on a benzene ring of a neighboring molecule thus creating dimers and connecting adjacent hydrogen bonded chains. As pointed out previously, form I oxcarbazepine is isostructural to form I of dihydrocarbamazepine.
The experimental crystal structure of form II is very similar to the second lowest energy predicted structure from Cabeza et al. 13 The molecular conformation of form II is related to form I. The benzene rings are planar and the angle between the planes is 658. Consistent with the vibrational spectroscopy, the carboxamide group adopts a hydrogen bonding scheme similar to that in form I with infinite chains parallel to the b-axis. The hydrogen bond ðO Á Á Á NÞ distance is 2.75 Å . Unlike form I, the hydrogen of the amide that does not participate in strong hydrogen bonding forms N À H Á Á Á p interactions. A major difference between the structures of form I and form II is the nature of the C À H Á Á Á O interactions. Instead of the dimers observed in form I, the carbonyl of the azepine ring interacts with two separate molecules from an adjacent chain, thus linking two different chains.
The structure of form III was never determined due to the small size and poor quality of the crystals. Crystal size and quality were unable to be improved upon, despite adjusting crystallization parameters and attempting seeding. The packing motif observed in forms I and II of oxcarbazepine differs greatly from that seen in carbamazepine and some of its other derivatives. One major difference from carbamazepine is the asymmetry of azepine ring in OCB. This leads to a greater puckering of the azepine ring on one side of the molecule. This is thought to allow for the optimization of the hydrogen bonding in a chain motif. 13 All three structures of dihydrocarbamazepine also exhibit an analogous hydrogen bonding scheme to OCB, as they all form hydrogen bonded chains. [7] [8] [9] The hydrogen bonding in all four of the carbamazepine polymorphs favor an anti-dimer motif, 6 whereas the structure of epoxycarbamazepine displays a twisted syn-dimer configuration. 18 In contrast to carbamazepine, dihydrocarbamazepine form I is almost isostruc- tural to OCB form I and exhibits a similar conformation of the azepine ring. 13 Hydroxycarbamazepine, although similar to OCB and epoxycarbamazepine in the fact that it adds an additional functional group that can participate in hydrogen bonding, differs from these structures as it actually hydrogen bonds through the alcohol in addition the carboxamide functionality and thus forms neither anti-dimers nor chains. 19 
CONCLUSION
OCB is at minimum trimorphic and two of these forms are structurally characterized. While the crystal structure for form III remains elusive, the presence of this form has been confirmed through multiple methods. The packing motif for forms I and II differ from those observed in the polymorphs of carbamazepine. This shows that although the basic molecular structure of carbamazepine and oxcarbazepine are similar, the change from a double bond bridge to an alkyl carbonyl is significant in the packing of the molecules. Because oxcarbazepine, dihydrocarbamazepine, and carbamazepine are polymorphic, the basic backbone of the molecules should be considered a polymorphophore.
14 Additional work is needed to verify all of the polymorphic forms reported in the patent literature. 
